Al­ler­gan dou­bles down on NM­DA de­pres­sion drug de­vel­op­ment ef­forts, bag­ging an op­tion to a small mol­e­cule fol­lowup ...

8 years ago
R&D
Pharma

Buoyed by he­mo­phil­ia A gene ther­a­py up­date, Bio­Marin switch­es to head-to-head study -- but shares slide on dura­bil­i­ty ...

8 years ago
R&D

Grail hauls in mon­ster $300M round from Chi­nese in­vestors amid ru­mors about Hong Kong IPO

8 years ago
Financing
China

New­com­er Do­va hus­tles a phar­ma castoff through to an FDA ap­proval, shares sink any­way

8 years ago
Pharma

Hunt­ing a cure, Spark re­ports steady progress on he­mo­phil­ia B gene ther­a­py as Pfiz­er preps for piv­otal hand­off

8 years ago
R&D

Wrestling with set­backs, Cel­gene adds $65M dis­cov­ery al­liance with Evotec to beef up on new can­cer drugs

8 years ago
R&D
Pharma

Bay Area start­up Rain Ther­a­peu­tics nabs $18M Se­ries A to tar­get lung can­cer niche

8 years ago
Financing
Startups

GSK gets Eu­ro­pean OK for HIV drug Ju­lu­ca; Akari dealt non-com­pli­ance no­tice from Nas­daq

8 years ago
News Briefing

BD chief George Golumbes­ki is the lat­est top ex­ec to ex­it Cel­gene dur­ing man­age­ment over­haul

8 years ago
People

Long side­lined on man­u­fac­tur­ing penal­ties, As­traZeneca fi­nal­ly gets a green light for a po­ten­tial hy­per­kalemia ...

8 years ago
Pharma

Nabri­va goes 2 for 2 in Phase III an­tibi­ot­ic pro­gram, scor­ing on a key cat­a­lyst -- but shares plunge on safe­ty ...

8 years ago
R&D

Roche adds a stel­lar round of piv­otal da­ta on Hem­li­bra, look­ing to ex­pand its mar­ket for a po­ten­tial mega-block­buster

8 years ago
R&D

An­oth­er cheap, old drug is be­ing fresh­ened up for brand pric­ing in the US — and shares soar, briefly

8 years ago
Bioregnum
R&D

As­traZeneca drops or di­vests a slate of drugs in lat­est quar­ter­ly up­date; Pierre Fab­re ex­tends a di­ag­nos­tic ...

8 years ago
News Briefing

Ag­ile bris­tles af­ter FDA's third snub, promis­ing a fight for its con­tra­cep­tive

8 years ago
R&D

Roivant brings Pfiz­er vets Azoulay, Gul­fo in­to its C-suite; Aileron CEO Joseph Yanchik is out

8 years ago
Peer Review

Syn­dax is hit with a set­back dur­ing the AS­CO pre­view round as lead drug flops in mid-stage study

8 years ago
R&D

J&J ax­es its big BACE pro­gram in asymp­to­matic Alzheimer's pa­tients as the drum­beat of PhI­II fail­ures rolls on

8 years ago
R&D

Al­ler­gan faces fresh woes with Resta­sis patents as Wal­green, re­tail­ers file law­suit over 'an­ti­com­pet­i­tive con­duc­t'

8 years ago
Pharma

For­get RNA drugs. Ac­cent gets $40M to de­vel­op small mol­e­cules that mod­i­fy RNA in­stead

8 years ago
Financing
Startups

Am­gen, No­var­tis ready to roll as FDA green lights block­buster cam­paign for mi­graine drug — priced at $6,900

8 years ago
Pharma

Who’s de­lay­ing gener­ic com­pe­ti­tion? FDA pub­lish­es a long list of drug­mak­ers they say gamed the sys­tem

8 years ago
Pharma

Why would Co­hen reach out to No­var­tis, but not Roche?; WuXi Bi­o­log­ics blue­prints big R&D/man­u­fac­tur­ing com­plex

8 years ago
News Briefing

FDA faults IQVIA for er­rors in opi­oid sales da­ta, calls for qual­i­ty re­view

8 years ago
Pharma
First page Previous page 1046104710481049105010511052 Next page Last page
A service from the Financial Times